Bromsite®
Bromfenac 0.075% · ophthalmic solution
NSAID
Approved uses
Postoperative inflammation and prevention of ocular pain after cataract surgery
One drop BID, morning and evening, to the affected eye starting 1 day before surgery, on the day of surgery, and for 14 days after surgery.
Left 77% pain-free by day 1 and cleared anterior chamber cells in 57% by day 15.
Contraindications
None listed on the FDA label.
0.075% ophthalmic solution, 5 mL in a 7.5 mL dropper bottle, foil pouch
Nonsteroidal anti-inflammatory drug whose action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. It is formulated in DuraSite as a viscous liquid that contains polycarbophil. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation, and in animal eyes they have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Warnings & Precautions
- Keratitis and corneal reactions: Topical NSAIDs may cause keratitis, and continued use in susceptible patients may progress to epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, any of which may be sight threatening. Discontinue immediately on evidence of corneal epithelial breakdown and monitor corneal health closely.
- Corneal adverse events: Postmarketing experience suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases such as dry eye syndrome, rheumatoid arthritis, or repeat ocular surgeries within a short period may be at increased risk for corneal adverse events which may become sight threatening; use with caution in these patients. Use more than 24 hours before or beyond 14 days after surgery may also increase this risk.
- Slow or delayed healing: All topical NSAIDs may slow or delay healing, and topical corticosteroids are also known to slow or delay healing; concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
- Cross-sensitivity: Potential cross-reactivity with acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs; use caution in patients who have reacted to these drugs.
- Increased bleeding time: With some NSAIDs there is the potential for increased bleeding time due to interference with platelet aggregation, and there have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues, including hyphemas, in conjunction with ocular surgery. Use caution with known bleeding tendencies or other medications that may prolong bleeding time.
- Contact lens wear: Not to be administered while wearing contact lenses; the benzalkonium chloride preservative may be absorbed by soft lenses.
Common Side Effects
The most commonly reported adverse reactions, in 1% to 8% of patients, were anterior chamber inflammation, headache, vitreous floaters, iritis, eye pain, and ocular hypertension.
Pregnancy: No adequate and well-controlled studies in pregnant women; avoid during late pregnancy because prostaglandin synthesis inhibitors can close the fetal ductus arteriosus. Oral dosing in rats and rabbits produced no structural teratogenicity at clinically relevant doses, though embryo-fetal lethality occurred in both species at the highest doses tested. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production; systemic exposure from ocular dosing is low.
Safety and efficacy below age 18 not established.